臨床研究等提出・公開システム

Japan post-marketing study of Peficitinib use in RA patients study-MTX tapering

JASPER study-MTX tapering

Yamaoka Kunihiro

Kitasato University Hospial

1-15-1, Kitasato, Minami, Sagamihara, Kanagawa

yamaokak@gmail.com

Yamaoka Kunihiro

Kitasato University Hospial

1-15-1, Kitasato, Minami, Sagamihara, Kanagawa

+81-42-778-8111

JASPER-MTX@tri-kobe.org

Recruiting

Oct. 09, 2024

Observational

treatment purpose

1. Patients aged 20 years old and older as of the index date and the reason for receiving peficitinib during peficitinib PMS (SMR001) is RA
2. Patients who were administered MTX (oral formulation: 8 mg/week higher or subcutaneous injection preparation: 7.5 mg/week higher ) concomitantly at the start of initial administration with peficitinib 100 mg or 150 mg
3. Patients who are registered to Peficitinib PMS (SMR001)
4. Patients who provided written informed consent to study participation
5. Patients who have been followed up for at least 104 weeks from the index date (including those who are discontinued before 104 weeks)

1. Patients who were administered Peficitinib for diseases other than RA
2. Patients who were administered Peficitinib 50 mg from the index date to 104 weeks

Both

Rheumatoid arthritis

Rheumatoid arthritis

The change in CDAI

1)Adverse Events and adverse reactions after the start of peficitinib administration
2)DAS28-ESR
3)DAS28-CRP
4)SDAI
5)CDAI
6)The change in the subjective global assessment
7)The change in the physician global assessment
8)The change in tender joint count
9)The change in swollen joint count
10)The change in ESR
11)The change in CRP
12)Dose reduction
13)Association between the patient characteristics and MTX dose level reduction
14)Determination of Good response/Moderate response based on DAS28-ESR EULAR improvement criteria

+81-42-778-8273

Aug. 01, 2024

No

none